| Title: |
A Prospective, Open-Label Study to Evaluate Dual-Modality Treatment With Deoxycholic Acid (ATX-101) and Hyaluronic Acid (VYC-20L) for Overall Improvement in Jawline Contour |
| Authors: |
Goodman, Greg J; Roberts, Stefania; Cook, Natasha; Ashton, Mark; Alker, Lucille; Silberberg, Michael |
| Contributors: |
Allergan Aesthetics, an AbbVie Company; IL; AND; Jenna Bassett; LLC; HEALTH |
| Source: |
Aesthetic Surgery Journal Open Forum ; volume 7 ; ISSN 2631-4797 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2025 |
| Description: |
Background A poorly defined jawline and blunting of the submental angle by excess submental fat (SMF) contribute to the loss of jawline contour. The injectable adipocytolytic agent ATX-101 reduces SMF, and the hyaluronic acid filler VYC-20L restores facial volume in the chin and jaw. Objectives The objective of this study was to evaluate the benefits of ATX-101 followed by VYC-20L for improving overall jawline contour and definition. Methods In this Phase 4, prospective, open-label, multicenter trial, participants received 1 to 6 ATX-101 treatments (8 weeks apart), followed by VYC-20L with optional VYC-20L touch-up after 14 days. The primary endpoint was Allergan Loss of Jawline Definition Scale (ALJDS) responder rate (proportion achieving ≥1-point improvement from baseline in investigator-assessed ALJDS score 4 weeks after final VYC-20L treatment). Secondary and exploratory endpoints included clinician- and participant-assessed measures of jawline definition, satisfaction, skin laxity, and SMF. Treatment-emergent adverse events (TEAEs) were monitored. Results Overall, 53 adults were enrolled and treated. Among 42 evaluable participants, the ALJDS responder rate was 92.9% (95% CI, 80.5-98.5). Consistent improvement across a range of clinician- and participant-assessed scales was achieved, including improvements in SMF Rating Scale score, Submental Skin Laxity Grade, and Global Aesthetic Improvement Scale score. Improvements in FACE-Q Satisfaction with Lower Face and Jawline and Appraisal of Area Under Chin indicated high levels of patient satisfaction. All participants experienced at least 1 TEAE; the majority of TEAEs were moderate in severity. Conclusions Sequential treatment with ATX-101 and VYC-20L may be effective for improving overall jawline contour and definition, with an acceptable safety profile. Level of Evidence: 2 (Therapeutic) |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/asjof/ojaf081 |
| DOI: |
10.1093/asjof/ojaf081/63615719/ojaf081.pdf |
| Availability: |
https://doi.org/10.1093/asjof/ojaf081; https://academic.oup.com/asjopenforum/advance-article-pdf/doi/10.1093/asjof/ojaf081/63615719/ojaf081.pdf; https://academic.oup.com/asjopenforum/article-pdf/doi/10.1093/asjof/ojaf081/63615719/ojaf081.pdf |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.1B94C543 |
| Database: |
BASE |